Collegium Pharmaceutical, Inc. COLL 深 滬
等待開盤 08-10 09:30:00 美东时间
29.47
+0.360
+1.24%
華盛通- 最 高29.81
- 今 開29.01
- 成交量 97.85万股
- 最 低 28.01
- 昨 收 29.11
- 總市值 9.56亿
- 52周最高 50.7866
- 市盈率 靜 16.99
- 換手率 3.02%
- 52周最低 28.01
- 委 比 77.65%
- 總股本 3243.38万
- 歷史最高 50.7866
- 量 比 1.35
- 振 幅 6.18%
- 歷史最低 7.37
- 每 手 1
- 風險率 5.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $46
Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $56 to $46.
08-07 02:20
Collegium Pharmaceutical shares are trading higher after the company reported better-than-expected Q1 financial results.
Collegium Pharmaceutical shares are trading higher after the company reported b...
05-07 21:04
美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
Collegium To Acquire AZSTARYS For $650M In Cash With Potential For Additional Milestone Payments Up To $135M Depending On Future Commercial And Regulatory Milestones
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio –– Enables Greater Impact Across ADHD Patient Communities –– AZSTARYS Expected to Generate
03-19 20:02
美股大行评级 | 最高300美元！大摩、小摩、花旗纷纷上调英伟达目标价；赛富时、C3.ai、Snowflake、Trade Desk等遭数十家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从47美元升至49美元；Citizens：维持Ironwood医药"跑赢大市"评级，目标价从8美元升至10美元
02-27 11:07
Deep Dive Into Collegium Pharmaceutical Stock: Analyst Perspectives (5 Ratings)
In the preceding three months, 5 analysts have released ratings for Collegium P...
02-27 04:00
Collegium Pharmaceutical Sees FY2026 Sales $805.000M-$825.000M vs $808.877M Est
Collegium Pharmaceutical (NASDAQ:COLL) sees FY2026 sales of $805.000 million-$825.000 million vs $808.877 million analyst estimate.
02-26 20:34
Insights into Collegium Pharmaceutical Q4 Earnings
Collegium Pharmaceutical (NASDAQ:COLL) just disclosed its Q4 earnings on Thursd...
02-26 20:34
Collegium Pharmaceutical Q4 Adj. EPS $2.04 Misses $2.33 Estimate, Sales $205.449M Miss $206.362M Estimate
Collegium Pharmaceutical (NASDAQ:COLL) reported quarterly earnings of $2.04 per share which missed the analyst consensus estimate of $2.33 by 12.37 percent. This is a 15.25 percent increase over earnings of $1.77 per
02-26 20:33
